JP2021515037A5 - - Google Patents

Info

Publication number
JP2021515037A5
JP2021515037A5 JP2020567462A JP2020567462A JP2021515037A5 JP 2021515037 A5 JP2021515037 A5 JP 2021515037A5 JP 2020567462 A JP2020567462 A JP 2020567462A JP 2020567462 A JP2020567462 A JP 2020567462A JP 2021515037 A5 JP2021515037 A5 JP 2021515037A5
Authority
JP
Japan
Prior art keywords
lipid
composition according
liposomes
composition
unsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020567462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515037A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/019609 external-priority patent/WO2019165436A1/en
Publication of JP2021515037A publication Critical patent/JP2021515037A/ja
Publication of JP2021515037A5 publication Critical patent/JP2021515037A5/ja
Ceased legal-status Critical Current

Links

JP2020567462A 2018-02-26 2019-02-26 寛容原性リポソーム及びその使用方法 Ceased JP2021515037A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862635376P 2018-02-26 2018-02-26
US62/635,376 2018-02-26
US201862755946P 2018-11-05 2018-11-05
US62/755,946 2018-11-05
PCT/US2019/019609 WO2019165436A1 (en) 2018-02-26 2019-02-26 Tolerogenic liposomes and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2021515037A JP2021515037A (ja) 2021-06-17
JP2021515037A5 true JP2021515037A5 (cg-RX-API-DMAC7.html) 2022-03-07

Family

ID=67688562

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567462A Ceased JP2021515037A (ja) 2018-02-26 2019-02-26 寛容原性リポソーム及びその使用方法

Country Status (9)

Country Link
US (1) US12178908B2 (cg-RX-API-DMAC7.html)
EP (1) EP3758682A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021515037A (cg-RX-API-DMAC7.html)
KR (1) KR20200139679A (cg-RX-API-DMAC7.html)
CN (1) CN112384204B (cg-RX-API-DMAC7.html)
AU (1) AU2019225251A1 (cg-RX-API-DMAC7.html)
CA (1) CA3092372A1 (cg-RX-API-DMAC7.html)
IL (1) IL276957B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019165436A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515037A (ja) 2018-02-26 2021-06-17 アントルクス,インコーポレーテッド 寛容原性リポソーム及びその使用方法
US10736847B2 (en) 2018-07-03 2020-08-11 Becton, Dickinson And Company Inverting device for liposome preparation by centrifugation
EP3999054A4 (en) * 2019-07-16 2023-07-26 Antolrx, Inc. IMMUNE TOLERANCE AGENTS AND POTENTIALIZERS
CN113740525A (zh) * 2020-05-29 2021-12-03 中国药科大学 一种检测肾损伤标志物胱抑素c的方法
US20230391783A1 (en) * 2021-05-27 2023-12-07 Shandong University Compound containing 2,4-thiazole ring, preparation method therefor, and application thereof
WO2024026452A1 (en) 2022-07-29 2024-02-01 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes
WO2024110516A1 (en) * 2022-11-23 2024-05-30 Ahead Therapeutics, S.L. Tolerogenic composition
WO2025072849A1 (en) 2023-09-29 2025-04-03 Repertoire Immune Medicines, Inc. Mhc-presentable peptides associated with type 1 diabetes

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5849572A (en) 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5849561A (en) 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6562943B1 (en) * 1999-04-21 2003-05-13 Zycos, Inc. Peptide epitopes recognized by disease promoting CD4+ T lymphocytes
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
CA2448066A1 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
US20070129307A1 (en) 2001-06-22 2007-06-07 The University Of British Columbia Insulin epitopes for the treatment of type 1 diabetes
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
ES2348868T3 (es) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. Vectores retrovirales terapeuticos para terapia genica.
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
WO2005038035A2 (en) 2003-10-15 2005-04-28 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses
EP2573185A3 (en) 2005-02-16 2013-06-05 Lentigen Corporation Lentiviral vectors and their use
KR20080052512A (ko) 2005-05-23 2008-06-11 박신, 인크. 아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산
FI20050814A0 (fi) 2005-08-11 2005-08-11 Procollagen Oy Menetelmä nivelreumassa muodostuvien kollageeniautovasta-aineiden havaitsemiseksi
EP1974044B1 (en) 2005-12-12 2011-01-26 CANJI, Inc. Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
US7951925B2 (en) 2006-05-25 2011-05-31 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
CA2669746C (en) 2006-12-14 2017-05-16 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
US20100047256A1 (en) 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
ES2708856T3 (es) 2007-08-03 2019-04-11 Pasteur Institut Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales
ES2422291T3 (es) 2007-10-31 2013-09-10 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
WO2009076292A2 (en) 2007-12-07 2009-06-18 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
WO2009114321A2 (en) 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
JP2011519266A (ja) 2008-03-21 2011-07-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫反応の調節
WO2009146179A1 (en) 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
EP2342321B1 (en) 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
EA201100765A1 (ru) * 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
US8679837B2 (en) 2009-04-02 2014-03-25 University Of Florida Research Foundation, Inc. Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
WO2011036640A2 (en) 2009-09-24 2011-03-31 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
EP2486137B1 (en) 2009-10-05 2018-05-30 Ya-Fang Mei Replication-competent ad11p based viral vectors
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
ES2685611T3 (es) 2011-02-14 2018-10-10 The Children's Hospital Of Philadelphia Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
CN107320734A (zh) * 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
KR101873447B1 (ko) 2011-06-22 2018-07-03 삼성디스플레이 주식회사 신규한 화합물 및 이를 포함한 유기발광 소자
EP2836226B1 (en) 2012-02-24 2017-06-28 Fred Hutchinson Cancer Research Center Compositions and methods for the treatment of hemoglobinopathies
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
JP2015527296A (ja) 2012-03-26 2015-09-17 アメリカ合衆国 哺乳動物細胞へのパッケージングされたrnaの新規の送達
JP6342886B2 (ja) 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
US9738879B2 (en) 2012-04-27 2017-08-22 Duke University Genetic correction of mutated genes
WO2014043131A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of California Lentiviral vector for stem cell gene therapy of sickle cell disease
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
WO2014141244A1 (en) 2013-03-12 2014-09-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
BR112015026019A2 (pt) 2013-04-11 2017-07-25 Brigham & Womens Hospital Inc métodos e composições de tratamento de doenças autoimunes
US9873907B2 (en) 2013-05-29 2018-01-23 Agilent Technologies, Inc. Method for fragmenting genomic DNA using CAS9
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
WO2015089443A2 (en) 2013-12-12 2015-06-18 The Brigham And Women's Hospital, Inc. Treating neurodegenerative disease
US20160060358A1 (en) * 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance
EP3188749A4 (en) * 2014-09-03 2018-06-13 Moderna Therapeutics, Inc. Tolerogenic compositions and methods
US10555919B2 (en) 2014-11-12 2020-02-11 The Brigham And Women's Hospital, Inc. Melatonin in autoimmune disease
EP3274053A4 (en) * 2015-03-23 2018-12-05 The Brigham and Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
GB201506112D0 (en) 2015-04-10 2015-05-27 Midatech Ltd And Inst Nationale De La Sant� Et De Al Rech Medicale And University College Car Nanoparticle-based antigen specific immunotherapy
WO2016168670A2 (en) 2015-04-16 2016-10-20 Longevica Therapeutics Inc. Methods for extending lifespan and methods of screening known pharmacological agents for new uses
EP3095440B1 (en) * 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
US20170121683A1 (en) 2015-11-03 2017-05-04 Regents Of The University Of Minnesota Aryl hydrocarbon receptor disruption and enhancement
WO2019099977A2 (en) 2017-11-20 2019-05-23 Ariagen, Inc. Indole compounds and their use
JP2021515037A (ja) 2018-02-26 2021-06-17 アントルクス,インコーポレーテッド 寛容原性リポソーム及びその使用方法
TW202038943A (zh) 2018-11-19 2020-11-01 美商雅里俊公司 治療癌症之方法

Similar Documents

Publication Publication Date Title
Attwood et al. Soluble ligands as drug targets
JP7061163B2 (ja) Il-4r阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
JP2023027258A (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP2022037133A (ja) 改良された血清アルブミン結合剤
JP2021052808A (ja) mRNAによってコードされる抗体を送達するための方法及び組成物
JP2020096630A5 (cg-RX-API-DMAC7.html)
JP2008542278A5 (cg-RX-API-DMAC7.html)
JP2011521662A5 (cg-RX-API-DMAC7.html)
KR102967396B1 (ko) Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용
WO2021003082A1 (en) Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof
TW201243049A (en) Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
TW202613177A (zh) Gipr抗體及其與glp-1的融合蛋白質,以及其藥物組合物和應用
JPWO2020059847A5 (cg-RX-API-DMAC7.html)
AU2021221287A1 (en) Engineered anti-IL-2 antibodies
CN117659189A (zh) Gipr抗体及其与fgf21的融合蛋白,以及其药物组合物和应用
EP4180456A1 (en) Antibody binding to hepatitis b virus surface antigen and application of antibody
EP4605432A2 (en) Chemokine receptor 8 (ccr8) antibodies
JP2022513626A5 (cg-RX-API-DMAC7.html)
JP2012506237A (ja) Dc−signに対する結合特異性をもつリガンド
US20240181086A1 (en) Compositions and methods for delivering therapeutic polynucleotides
TWI895541B (zh) 包含抗原和其醣工程化抗體之免疫組合物
Wu et al. Half-life extension enhances drug efficacy in adeno-associated virus delivered gene therapy
EP4581044A1 (en) Compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (asc) and methods of use
US12098186B1 (en) Multivalent anti-SARS-CoV-2 nanobodies
JP7849919B2 (ja) ヒトdr3に特異的に結合する抗体及びその用途